Absci
About Absci
Absci is a clinical-stage biopharmaceutical company that leverages its Integrated Drug Creation™ platform, combining generative AI with synthetic biology to design and advance novel biologic therapeutics faster. They aim to create better biologics for patients by unifying drug discovery and cell line development into one simultaneous process.
Company Details
- Website
- https://www.absci.com
- Funding
- IPO
- Total Raised
- $228.18M
- Stock Ticker
- ABSI
- https://www.linkedin.com/company/absci
Specializations
- Biotechnology
- Generative AI
- Drug Discovery
- Synthetic Biology
- Protein Engineering
Products & Solutions (3)
| Product | Category | Sub-Category | Description |
|---|---|---|---|
| Absci Drug Creation | research-development | Drug Discovery AI | AI-powered de novo antibody generation |
| AI Target Discovery | research-development | Drug Discovery AI | Leveraging reverse immunology and generative AI to discover novel therapeutic targets. |
| Drug Creation Partnerships | research-development | Drug Discovery AI | Leverage Absci's AI and wet lab platform for rapid discovery of breakthrough biologics. |
Notable Customers
- AstraZeneca
- Merck
- Almirall
- AMD
- Oracle
- PrecisionLife
- Memorial Sloan Kettering Cancer Center
- Twist Bioscience
- Owkin
- Caltech
- Gates Foundation
- NVIDIA